drugset
Drugs / D013
last change Sep 2023 re-read 2 minutes ago

D013

Developed for
hyperlipidemia · essential hypertension
Investigated by
Chong Kun Dang Pharmaceutical

Trials 8 · a red edge is where a trial was stopped

today NCT05698043 · Ph 1 NCT05552495 · Ph 1 NCT05245084 · Ph 1 NCT04987970 · Ph 1 NCT04694989 · Ph 1 NCT04312698 · Ph 3 NCT03920579 · Ph 1 NCT03609606 · Ph 1
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT05698043 Jul → Sep 2023 hyperlipidemia, combined, 2 Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05552495 Sep → Nov 2022 hyperlipidemia, combined, 2 Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05245084 Mar → Jun 2022 hyperlipidemia, combined, 2 Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT04987970 Sep → Nov 2021 — Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT04694989 Feb → Apr 2021 hyperlipidemia, combined, 2 Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT03920579 Apr → May 2019 hyperlipidemia, hypertensive disorder Chong Kun Dang Pharmaceutical Unknown No outcome recorded
Phase 1 NCT03609606 Aug → Sep 2018 hyperlipidemia, hypertensive disorder Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 31 trial
Phase 3 NCT04312698 Aug 2019 → Jun 2021 hyperlipidemia Chong Kun Dang Pharmaceutical Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT04388215 Comparator Oct 2019 → Apr 2021 essential hypertension, hyperlipidemia Chong Kun Dang Pharmaceutical Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as D013 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05245084 ↗
8

NCT04312698 ↗

NCT03920579 ↗

NCT05698043 ↗

NCT04987970 ↗

NCT05552495 ↗

NCT04694989 ↗

NCT04388215 ↗

NCT03609606 ↗
Route Oral “Daily oral administration of 1 tablet” NCT03609606 ↗